Indian Journal of Novel Drug Delivery

IJNDD

An Official Publication of Karnataka Education and Scientific Society

Review Article

Advancements in Nanoemulsion-Based Transdermal Systems for Enhanced Anticonvulsant Therapy in Chronic Neuropathic Pain

PRIYANKA SHINDE, JAMEEL AHMAD S MULLA*

Department of Pharmaceutics, Shree Santkrupa College of Pharmacy, Ghogaon-Karad, Maharashtra –415111, India.

ARTICLE DETAILS

Article history:
Received on 16 August 2024
Modified on 22 September 2024
Accepted on 27 September 2024

Keywords:
Nanoemulsion,
Neuropathic pain,
Anticonvulsants,
Nanoemulsion-based transdermal systems.

ABSTRACT

Neuropathic pain (NP) is a chronic ailment due to somatosensory system dysfunction, affecting 7–8% of the global population. Conventional oral anticonvulsants like gabapentin, pregabalin, and carbamazepine exhibit limitations, including poor bioavailability, systemic side effects, and patient non-compliance. Nanoemulsion-based transdermal delivery systems offer a novel approach to overcoming these challenges by enhancing drug solubility, stability, and skin penetration. These isotropic colloidal systems, with droplet sizes of 20–200 nm, incorporate oils, surfactants, and cosurfactants to bypass the gastrointestinal tract, reduce first-pass metabolism, and achieve sustained drug release. Formulation techniques such as ultrasonication, microfluidization, and spontaneous emulsification ensure stable and uniform nanoemulsions for efficient transdermal drug delivery. This strategy addresses the limitations of oral administration while minimizing systemic side effects, improving patient compliance, and enabling localized pain relief. Despite these advantages, challenges persist, including stability issues, scalability, and regulatory hurdles. Future innovations, such as smart nanoemulsions, personalized medicine approaches, and green formulations, are poised to transform chronic pain management and enhance therapeutic outcomes.

INTRODUCTION

Neuropathic pain (NP) is among the most debilitating forms of chronic pain, representing a major unmet medical challenge. It results from damage or dysfunction of the somatosensory nervous system, leading to abnormal pain signal processing [1]. The International Association for the Study of Pain (IASP) defines NP as "pain arising as a direct consequence of a lesion or disease affecting the somatosensory system [2]. Chronic neuropathic pain (CNP), characterized by spontaneous pain, hyperalgesia, and sensory abnormalities, persists for more than three months and significantly impairs both physical and mental well-being [3].

Globally, NP affects approximately 7–8% of the population, and its prevalence varies by region and underlying conditions. In India, key contributing factors include diabetes, traumatic injuries, infections, and chronic illnesses. A survey using the DouleurNeuropathique 4 (DN4) questionnaire estimated that about 10% of individuals experiencing chronic pain also display neuropathic characteristics [4]. National data further indicate that approximately 13% of Indians live with chronic pain, with neuropathic components identified in nearly 30% of these cases [5]. Diabetic peripheral neuropathy (DPN), a prominent form of NP linked to diabetes mellitus, affects an estimated 29.2% of Indian patients with type 2 diabetes, though rates vary widely depending on diagnostic criteria [6].

NP arises from complex mechanisms at the peripheral and central levels [7]. Peripheral sensitization, triggered by nerve injury, induces inflammatory responses involving cytokines and prostaglandins, leading to increased excitability of peripheral neurons [8, 9]. This involves the upregulation of ion channels, such as sodium (Nav1.7, Nav1.8) and calcium channels, causing ectopic discharges and heightened pain sensitivity [10]. Central sensitization amplifies these signals through over activation of NMDA receptors and increased release of excitatory neurotransmitters like glutamate. Structural and functional changes in the spinal cord and brain, including altered synaptic connectivity and

Author for Correspondence:
Email: jameelahmed5@gmail.com

Table 1: Limitations of Oral Anticonvulsants

Limitation	Description	Example Drugs	Reference
Poor Bioavailability	Limited absorption in the GI tract; bioavailability decreases with higher doses.	Gabapentin	[19]
First-Pass Metabolism	Extensive liver metabolism reduces therapeutic efficacy, necessitating higher doses.	Carbamazepine	[20]
Systemic Side Effects	Non-specific distribution causes side effects like drowsiness, fatigue, and hepatotoxicity.	Pregabalin, Valproic Acid	[21]
Drug Interactions	Enzyme induction leads to interactions, reducing efficacy or increasing toxicity of co-administered drugs.	Carbamazepine	[22]
Variability in Plasma Levels	Fluctuations in drug levels cause suboptimal outcomes, including breakthrough seizures or pain episodes.	Topiramate	[23]
GI Irritation	Causes discomfort such as nausea and vomiting, reducing patient compliance.	Various Oral Drugs	[24]
Poor Patient Compliance	Frequent dosing and side effects lead to poor long-term adherence, especially in elderly or comorbid patients.	Various Oral Drugs	[25]

Table 2: Components of nanoemulsions [30]

Component	Role	Examples
Oils	Provide a solubilizing medium for lipophilic drugs.	Medium-chain triglycerides (MCTs), isopropyl myristate, castor oil.
Surfactants	Reduce interfacial tension between oil and water phases.	Tween 20, Tween 80 (non-ionic surfactants).
Co-surfactants	Enhance emulsification by further reducing interfacial tension.	Ethanol, propylene glycol, polyethylene glycol.
Drug Molecules	Loaded into the oil phase (hydrophobic or amphiphilic drugs).	Depends on the specific drug being delivered.

microglial activation, contribute to the persistence of pain. The loss of inhibitory control in the spinal cord further exacerbates nociceptive transmission [11, 12].

Anticonvulsants commonly prescribed for neuropathic pain include gabapentin, pregabalin, carbamazepine, oxcarbazepine, and lamotrigine. Gabapentin works by targeting the $\alpha2\delta$ subunit of voltage-gated calcium channels, effectively reducing excitatory neurotransmitter release, particularly in conditions like postherpetic neuralgia [13]. Pregabalin, a more potent derivative of gabapentin, offers improved efficacy and bioavailability, making it suitable for diabetic neuropathy, fibromyalgia, and spinal cord injury-related pain [14, 15]. Carbamazepine and oxcarbazepine block voltage-gated sodium channels, stabilizing hyperexcited neuronal membranes, and are particularly effective for trigeminal neuralgia [16, 17]. Lamotrigine, which inhibits voltage-gated sodium channels and reduces glutamate release, is used for post-stroke pain and painful diabetic neuropathy [18]. These anticonvulsants, with their distinct mechanisms, play a crucial role in alleviating chronic neuropathic pain symptoms.

Limitations of Oral Anticonvulsants

Table 1 shows the major limitations of oral anticonvulsant drugs.

Nanoemulsion-Based Transdermal Systems: Formulation Aspects

Nanoemulsions are isotropic, thermodynamically stable colloidal systems (20–200 nm droplet size) composed of oil, water, surfactants, and cosurfactants [26]. Their nanometric size provides high solubilization for hydrophobic drugs, optical clarity, and kinetic stability, making them ideal for transdermal drug delivery [27, 28]. By overcoming the skin barrier, nanoemulsions enhance drug penetration into systemic circulation through mechanisms like improved diffusion via small droplet size and increased permeability by surfactants disrupting the stratum corneum's lipid bilayer [29]. Table 2 shows components of nanoemulsions.

Formulation Techniques

Nanoemulsions for transdermal delivery are formulated using high-energy methods like ultrasonication and homogenization, or low-energy techniques such as phase inversion and spontaneous emulsification. These methods produce stable, uniform nanoemulsions that enhance drug penetration through the skin, enabling controlled, sustained release with reduced systemic side effects [31, 32].

High-energy Approach

1) High-pressure Homogenization

The most common technique for producing nanoemulsions uses a high-pressure or piston homogenizer (Fig. 1), achieving particle sizes as small as 1 nm [33]. A macroemulsion is forced through a narrow orifice at 500–5000 psi, where hydraulic shear, turbulence, and cavitation create ultra-small droplets [34].

2) Microfluidization

Microfluidization is a high-pressure mixing technique using a microfluidizer (Fig. 2). It forces a coarse emulsion (created by blending aqueous and oily phases) through microchannels at pressures of 500–20,000 psi, breaking it into fine particles in the sub-micron range. The emulsion is processed repeatedly to achieve the desired particle size and then filtered under nitrogen to produce a stable and uniform nanoemulsion [35].

3) Ultrasonication

Ultrasonic emulsification is a high-energy method utilizing sound waves (>20 kHz) and acoustic cavitation via a sonotrode (Fig. 3). Collapse of cavitation bubbles generates shock waves that break coarse droplets into nano-sized ones [36, 37]. Droplet size is controlled by optimizing oil concentration, emulsifier concentration, oil-to-surfactant ratio, viscosity, emulsification time, and energy input. Megasonic irradiation (MHz range) enables surfactant-free, stable, transparent nanoemulsions [38].

Low Energy Approaches

1) Spontaneous Emulsification

Spontaneous emulsification is a low-energy technique for preparing nanoemulsions at room temperature without specialized equipment [39, 40]. It involves gradually adding water to an oil-surfactant mixture with gentle stirring to form oil-in-water (O/W) nanoemulsions (Fig 4). The process depends on factors like interfacial tension, viscosity, phase transitions, and surfactant properties [41]. However, its key limitations include a restricted oil phase and the use of solvents [42, 43].

2) The Phase Inversion Temperature (PIT)

The Phase Inversion Temperature (PIT) method is a low-energy technique for producing nanoemulsions by adjusting surfactant curvature through temperature changes at constant composition (Fig. 5). Unlike Spontaneous Emulsification (SE), it avoids organic solvents [44, 45] and surpasses the Phase Inversion Composition (PIC) method in achieving smaller droplet sizes and lower polydispersity index (PDI) [46].

3) Membrane Emulsification

The membrane emulsion technique is a promising method for nanoemulsion preparation, leveraging controlled droplet formation through a porous membrane. In this approach, the dispersed phase is forced through the membrane pores into the continuous phase under controlled pressure, producing uniform droplets. This technique allows for precise control over droplet size and distribution, essential for stable and efficient nanoemulsions. The process is scalable, reproducible, and adaptable, offering significant advantages in pharmaceutical, cosmetic, and food applications for encapsulating hydrophobic drugs and nutrients [47, 48].

Advantages of Nanoemulsions

1. ***Enhanced Solubility and Stability:*** Nanoemulsions improve the solubility and stability of hydrophobic drugs, reducing reliance on harsh organic solvents.
2. ***Deeper Skin Penetration:*** Nanoscale droplet size facilitates effective delivery of both lipophilic and hydrophilic drugs through the skin.
3. ***Improved Bioavailability:*** By bypassing the gastrointestinal tract, nanoemulsions minimize first-pass metabolism and enhance bioavailability.
4. ***Safety and Minimal Irritation:*** Biocompatible excipients ensure safe application and reduce skin irritation [49].
5. ***Applications in Therapy:*** Effective in chronic pain management and hormone replacement therapy [50].
6. ***Gastrointestinal Side Effects Reduction***: Improves solubility, permeability, and bioavailability of lipophilic drugs like valdecoxib, minimizing GI side effects [51].



Figure 1: High-pressure homogenization



Figure 2: Microfluidization



Figure 3: Ultrasonication



Figure 4: Spontaneous emulsification



Figure 5: Phase Inversion Temperature (PIT)

Transdermal Drug Delivery Systems in Chronic Pain Management

Transdermal drug delivery systems (TDDS) have revolutionized chronic pain management by providing a non-invasive and effective means of drug administration. Chronic pain, typically lasting more than three months, requires sustained therapeutic regimens. TDDS have emerged as an advantageous alternative, offering unique benefits for patients and healthcare providers.

1. ***Improved Drug Absorption & Bioavailability:*** TDDS bypass first-pass metabolism, enhancing bioavailability [52].
2. ***Sustained & Controlled Release:*** Ensures continuous drug release, reducing dosing frequency and improving compliance [53].
3. ***Reduction of Systemic Side Effects:*** Minimizes systemic side effects like gastrointestinal irritation with NSAIDs [54].

4. ***Enhanced Patient Compliance:*** Convenient for chronic pain management, improving adherence.
5. ***Localized Pain Relief:*** Targeted relief (e.g., lidocaine, NSAID patches) with minimal systemic exposure [55].
6. ***Versatility in Drug Candidates:*** Effective for opioids, analgesics, and adjuvants like gabapentin [56].
7. ***Reduced Risk of Drug Abuse:*** Prevents misuse through controlled, sustained release [57].
8. ***Minimized Dose-Dependent Fluctuations:*** Stabilizes plasma drug concentrations, reducing side effects [58].

Examples of TDDS in Chronic Pain Management

Several FDA-approved transdermal systems demonstrate clinical efficacy in chronic pain:

- ***Fentanyl and Buprenorphine Patches:*** These are widely used for managing severe pain, especially in oncology settings [59].
- ***Lidocaine Patches:*** Commonly used for localized neuropathic pain conditions, such as postherpetic neuralgia [60].
- ***NSAID Patches:*** Provide effective relief in musculoskeletal pain and arthritis [61].
- ***Buprenorphine Patch:*** Partial μ-opioid receptor agonist for chronic non-cancer and cancer pain with reduced respiratory depression [62].
- ***Capsaicin Patch (Qutenza):*** High-concentration patch for neuropathic pain; desensitizes nociceptive neurons [63].
- ***Diclofenac Epolamine Patch***: Targets acute musculoskeletal pain with localized anti-inflammatory action [64].
- ***Clonidine Patch:*** α2-adrenergic agonist for chronic neuropathic pain like CRPS, offering prolonged relief [65].

Challenges and Limitations

- Stability Issues: Nanoemulsions are thermodynamically unstable systems, which may lead to phase separation, Ostwald ripening, or drug precipitation over time. These stability concerns can hinder the consistency of drug delivery [66].
- Skin Permeation Challenges: Despite the advanced penetration-enhancing properties of nanoemulsions, the skin's stratum corneum remains a significant barrier. The permeation efficacy may vary depending on the physicochemical properties of the drug and the formulation's composition [67].
- Toxicity of Excipients: The surfactants and co-surfactants used in nanoemulsion formulations may cause skin irritation or toxicity upon prolonged use, particularly when used for chronic conditions like neuropathic pain [68].
- Scalability and Cost: The production of nanoemulsions often requires sophisticated equipment and stringent manufacturing conditions, leading to increased costs and challenges in scaling up from laboratory to industrial production [35].
- Drug Loading and Release: Limited drug-loading capacity can restrict the therapeutic efficacy of nanoemulsions for chronic pain management. Additionally, achieving controlled and sustained release profiles remains a challenge in transdermal systems [69].
- Regulatory and Approval Hurdles: Nanoemulsion-based formulations face rigorous regulatory scrutiny due to the involvement of nanotechnology. The lack of standardized guidelines further complicates the approval process [45].
- Patient Compliance: Although transdermal systems are non-invasive, factors such as patch adhesion, skin irritation, and dosing frequency may affect patient compliance, particularly in long-term therapy for chronic conditions [70].
- Long-Term Safety: The potential for long-term exposure to nanoscale materials remains underexplored, raising concerns about systemic toxicity, bioaccumulation, and long-term side effects [71].

Future Directions and Innovations

- Development of Smart Nanoemulsions- The integration of stimuli-responsive materials (e.g., temperature, pH, or light-sensitive components) into nanoemulsion-based formulations could enable controlled and on-demand drug release, enhancing therapeutic precision [72].

- Advanced Skin Penetration Techniques- Combining nanoemulsions with novel penetration enhancement strategies, such as microneedles or ultrasound-mediated delivery, could improve drug permeation across the skin barrier, making transdermal anticonvulsant therapy more effective [73].
- Personalized Medicine Approaches- Leveraging advances in pharmacogenomics and artificial intelligence, future nanoemulsion-based transdermal systems can be tailored to individual patient needs, optimizing drug delivery parameters and minimizing side effects [74].
- Green and Biocompatible Formulations- The focus on sustainability in pharmaceutical development may drive the use of natural, biodegradable, and eco-friendly surfactants and co-surfactants in nanoemulsion systems, reducing toxicity and environmental impact [75].
- Incorporation of Multifunctional Therapeutics- Future nanoemulsion-based transdermal systems may include multifunctional drugs with neuroprotective, anti-inflammatory, and anticonvulsant properties to provide holistic treatment for neuropathic pain [76].
- Integration with Wearable Devices- Coupling nanoemulsion patches with wearable biosensors could allow real-time monitoring of drug release and therapeutic outcomes, ensuring optimal management of chronic neuropathic pain [77].
- Regulatory Framework Innovations- Establishing harmonized and streamlined regulatory guidelines for nanoemulsion-based systems can facilitate their rapid development and approval, paving the way for broader clinical adoption [78].

CONCLUSION

Nanoemulsion-based transdermal systems represent a promising alternative for chronic neuropathic pain management. By overcoming the limitations of oral anticonvulsants and providing sustained, localized drug delivery, these systems improve therapeutic efficacy and patient compliance. Continued research and innovation in formulation techniques and regulatory frameworks will further optimize their clinical adoption and impact.

REFERENCES

[1] Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D, et al. Neuropathic pain. Nat Rev Dis Primers. 2017; 3:17002.

[2] Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630–5.

[3] Azanjac-Arsić. Neuropathic pain: Definition, classification and treatment. Galenika Med J. 2024;3(9):28-33.

[4] Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008;136(3):380–7.

[5] Kumari S, Kumar R, Sharma D. Text neck syndrome: the pain of modern era. Int J Health Sci Res. 2021;11(11):161-5.

[6] Sun J, Wang Y, Zhang X, Zhu S, He H. Prevalence of peripheral neuropathy in patients with diabetes: A systematic review and meta-analysis. Prim Care Diabetes. 2020;14(5):1-8.

[7] Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci. 2009;32:1–32.

[8] Wong CS, Hui GK, Chung EK, Wong SH. Diagnosis and management of neuropathic pain. Pain Manag. 2014;4(3):221–31.

[9] Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci. 2007;10(11):1361–8.

[10] Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9(8):807–19.

[11] Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009;10(9):895-926.

[12] Kuner R, Flor H. Structural plasticity and reorganisation in chronic pain. Nat Rev Neurosci. 2016;18(1):20-30.

[13] Serpell MG; Neuropathic Pain Study Group. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain. 2002;99(3):557-566.

[14] Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-173.

[15] Mulla JS, Pujari P, Sangar OS. An Overview of the Transdermal Drug Delivery System. Int J Creat Res Thoughts. 2022;10(5):a497-a507.

[16] Rana MH, Khan AAG, Khalid I, Ishfaq M, Javali MA, Baig FAH, et al. Therapeutic Approach for Trigeminal Neuralgia: A Systematic Review. Biomedicines. 2023;11(10):2606.

[17] Jadhav VU, Jamakandi VG, Mulla JA, Borkar SN, Karpe P, Suresh R, et al. Reservoir Type Nicorandil Transdermal Delivery System By Using Permeation Enhancers. Indian Drugs. 2009;46(9):23-31.

[18] Eisenberg E, Lurie Y, Braker C, Daoud D, Ishay A. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology. 2001;57(3):505-509.

[19] Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr OpinPharmacol. 2006;6(1):108-113.

[20] Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003;2(8):473-481.

[21] Johannessen SI, Landmark CJ. Antiepileptic drug interactions - principles and clinical implications. Curr Neuropharmacol. 2010;8(3):254-267.

[22] Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61(3):246-255.

[23] Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov. 2010;9(1):68-82.

[24] Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11(9):792-802.

[25] Al-Aqeel S, Gershuni O, Al-Sabhan J, Hiligsmann M. Strategies for improving adherence to antiepileptic drug treatment in people with epilepsy. Cochrane Database Syst Rev. 2020;10(10): CD008312.

[26] Shirke SN, Mulla JAS. Intranasal nanoemulsion for brain targeting: A review. Indian J Novel Drug Deliv. 2023;15(1):1-11.

[27] Kheradkar VA, Mulla JAS. Nanosuspension: A Novel Technology for Drug Delivery. Asian J Res Pharm Sci. 2023;13(2):106-110.

[28] Chakorkar SS, Mulla JASG. Cubosome-based Corticosteroidal Drug Delivery System for Sustained Ocular Delivery: A Pharmacokinetic Investigation. Indian J Pharm Educ Res. 2024;58(2s):s502-s514.

[29] Shakeel F, Baboota S, Ahuja A, Ali J, Shafiq S. Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsion. J Nanobiotechnol. 2008;6(1):8.

[30] McClements DJ. Nanoemulsions versus microemulsions: terminology, differences, and similarities. Soft Matter. 2012;8(6):1719-29.

[31] Shaker DS, Ishak RAH, Ghoneim A, Elhuoni MA. Nanoemulsion: A Review on Mechanisms for the Transdermal Delivery of Hydrophobic and Hydrophilic Drugs. Sci Pharm. 2019;87(3):17.

[32] Kumar M, Bishnoi RS, Shukla AK, Jain CP. Techniques for Formulation of Nanoemulsion Drug Delivery System: A Review. Prev Nutr Food Sci. 2019;24(3):225-34.

[33] Mali JD, Mulla JAS. Ocular drug delivery system: A review. World J Drug Target. 2013;1(1):9-24.

[34] Chime SA, Kenechukwu FC, Attama AA. Nanoemulsions-Advances in Formulation, Characterization and Applications in Drug Delivery. In: Ali DS, editor. Application of Nanotechnology in Drug Delivery. Croatia: InTech; 2014. p. 77-111.

[35] Alhamdany TA, Saeed AMH, Alaayedi M. Nanoemulsion and Solid Nanoemulsion for Improving Oral Delivery of a Breast Cancer Drug: Formulation, Evaluation, and a Comparison Study. Saudi Pharm J. 2021;29(11):1278-88.

[36] Mhoprekar JD, Mulla JAS. Nanosponges drug delivery: A concise review. World J Nanopart Res. 2023;1(1):17-28.

[37] Shingate DM, Mulla JAS. Exploring Liposomes: Comprehensive Classification, Preparation Techniques, and Composition Insights. Indian J Novel Drug Deliv. 2024;16(2):80-90.

[38] Ghosh V, Mukherjee A, Chandrasekaran N. Ultrasonic emulsification of food-grade nanoemulsion formulation and evaluation of its bactericidal activity. UltrasonSonochem. 2013;20(1):338-44.

[39] Mulla JAS, Chalke PM, Londhe SP, Patil MA, Nalawade SN, Sawant RR. Design and Optimization of Nanosponges of Poorly Soluble Voriconazole Using Central Composite Design. Indian J Novel Drug Deliv. 2023;15(4):189-99.

[40] Mulla JAS, Khazi MIA, Khan AY, Gong YD, Khazi IAM. Design, Characterization and *In vitro* Evaluation of Imidazo[2,1-b][1,3,4]thiadiazole Derivative Loaded Solid Lipid Nanoparticles. Drug Invent Today. 2012;4(8):420-3.

[41] Bouchemal K, Briançon S, Perrier E, Fessi H. Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimisation. Int J Pharm. 2004;280(1-2):241-51.

[42] Anton N, Benoit JP, Saulnier P. Design and production of nanoparticles formulated from nano-emulsion templates-a review. J Control Release. 2008;128(3):185-99.

[43] Mehanna MM, Mneimneh AT. Formulation and Applications of Lipid-Based Nanovehicles: Spotlight on Self-emulsifying Systems. Adv Pharm Bull. 2021;11(1):56-67.

[44] Ganta S, Talekar M, Singh A, Coleman TP, Amiji MM. Nanoemulsions in translational research-opportunities and challenges in targeted cancer therapy. AAPS PharmSciTech. 2014;15(3):694-708.

[45] Pereira SF, Barroso A, Mourão RHV, Fernandes CP. A Low Energy Approach for the Preparation of Nano-Emulsions with a High Citral-Content Essential Oil. Molecules. 2021;26(12):3666.

[46] Roger K, Cabane B, Olsson U. Emulsification through surfactant hydration: the PIC process revisited. Langmuir. 2011;27(2):604-11.

[47] Tayeb HH, Felimban R, Almaghrabi S, Hasaballah N. Nanoemulsions: Formulation, characterization, biological fate, and potential role against COVID-19 and other viral outbreaks. Colloid Interface Sci Commun. 2021; 45:100533.

[48] Wolska J, Falizi NJ. Membrane Emulsification Process as a Method for Obtaining Molecularly Imprinted Polymers. Polymers. 2021;13(16):2830.

[49] Rai VK, Mishra N, Yadav KS, Yadav NP. Nanoemulsion as pharmaceutical carrier for dermal and transdermal drug delivery: Formulation development, stability issues, basic considerations and applications. J Control Release. 2018; 270:203-25.

[50] Bennett MI, Simpson KH. Gabapentin in the treatment of neuropathic pain. Palliat Med. 2004;18(1):5-11.

[51] Mishra VVBK, Bhanja SB, Panigrahi BB. Development and Evaluation of Nanoemulsion gel for transdermal delivery of Valdecoxib. Res J Pharm Tech. 2019;12(2):600-610.

[52] Hu W, Bian Q, Zhou Y, Gao J. Pain management with transdermal drug administration: A review. Int J Pharm. 2022; 618:121696.

[53] Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261-8.

[54] Hadgraft J. Skin, the final frontier. Int J Pharm. 2001;224(1-2):1-18.

[55] Tan X, Feldman SR, Chang J, Balkrishnan R. Topical drug delivery systems in dermatology: a review of patient adherence issues. Expert Opin Drug Deliv. 2012;9(10):1263-71.

[56] Stark CW, Isaamullah M, Hassan SS, Dyara O, Abd-Elsayed A. A Review of Chronic Pain and Device Interventions: Benefits and Future Directions. Pain Ther. 2023;12(2):341-54.

[57] Gill HS, Prausnitz MR. Coating formulations for microneedles. Pharm Res. 2007;24(7):1369-80.

[58] Alkilani AZ, McCrudden MT, Donnelly RF. Transdermal Drug Delivery: Innovative Pharmaceutical Developments Based on Disruption of the Barrier Properties of the Stratum Corneum. Pharmaceutics. 2015;7(4):438-70.

[59] Ruggiero A, Coccia P, Arena R, Maurizi P, Battista A, Ridola V, et al. Efficacy and safety of transdermal buprenorphine in the management of children with cancer-related pain. Pediatr Blood Cancer. 2013;60(3):433-7.

[60] Garnock-Jones KP, Keating GM. Lidocaine 5% medicated plaster: a review of its use in postherpetic neuralgia. Drugs. 2009;69(15):2149-65.

[61] McPherson ML, Cimino NM. Topical NSAID formulations. Pain Med. 2013;14 Suppl1:S35-9.

[62] Sittl R. Transdermal buprenorphine in the treatment of chronic pain. Expert Rev Neurother. 2005;5(3):315-23.

[63] Simpson DM, Brown S, Tobias J, NGX-4010 C107 Study Group. Controlled trial of high-concentration capsaicin patch for

treatment of painful HIV neuropathy. Neurology. 2008;70(24):2305-13.

[64] de Sire A, Marotta N, Lippi L, Scaturro D, Farì G, Liccardi A, et al. Pharmacological Treatment for Acute Traumatic Musculoskeletal Pain in Athletes. Medicina (Kaunas). 2021;57(11):1208.

[65] Wrzosek A, Woron J, Dobrogowski J, Jakowicka-Wordliczek J, Wordliczek J. Topical clonidine for neuropathic pain. Cochrane Database Syst Rev. 2015;8(8):CD010967.

[66] Choi SJ, McClements DJ. Nanoemulsions as delivery systems for lipophilic nutraceuticals: strategies for improving their formulation, stability, functionality and bioavailability. Food Sci Biotechnol. 2020;29(2):149-68.

[67] Bhansali D, Teng SL, Lee CS, Schmidt BL, Bunnett NW, Leong KW. Nanotechnology for Pain Management: Current and Future Therapeutic Interventions. Nano Today. 2021;39:101223.

[68] Pulingam T, Foroozandeh P, Chuah JA, Sudesh K. Exploring Various Techniques for the Chemical and Biological Synthesis of Polymeric Nanoparticles. Nanomaterials (Basel). 2022;12(3):576.

[69] Preeti, Sambhakar S, Malik R, Bhatia S, Al Harrasi A, Rani C, et al. Nanoemulsion: An Emerging Novel Technology for Improving the Bioavailability of Drugs. Scientifica. 2023; 2023:6640103.

[70] Talegaonkar S, Azeem A, Ahmad FJ, Khar RK, Pathan SA, Khan ZI. Microemulsions: a novel approach to enhanced drug delivery. Recent Pat Drug Deliv Formul. 2008;2(3):238-57.

[71] Ezike TC, Okpala US, Onoja UL, Nwike CP, Ezeako EC, Okpara OJ, et al. Advances in drug delivery systems, challenges and future directions. Heliyon. 2023;9(6):e17488.

[72] Gu M, Wang X, Toh TB, Chow EK. Applications of stimuli-responsive nanoscale drug delivery systems in translational research. Drug Discov Today. 2018;23(5):1043-52.

[73] Jung JH, Jin SG. Microneedle for transdermal drug delivery: current trends and fabrication. J Pharm Investig. 2021;51(5):503-17.

[74] Serrano DR, Luciano FC, Anaya BJ, Ongoren B, Kara A, Molina G, et al. Artificial Intelligence (AI) Applications in Drug Discovery and Drug Delivery: Revolutionizing Personalized Medicine. Pharmaceutics. 2024;16(10):1328.

[75] Kanwar R, Rathee J, Salunke DB, Mehta SK. Green Nanotechnology-Driven Drug Delivery Assemblies. ACS Omega. 2019;4(5):8804-15.

[76] Ganta S, Deshpande D, Korde A, Amiji M. A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers. Mol Membr Biol. 2010;27(7):260-73.

[77] Khadka B, Lee B, Kim KT. Drug Delivery Systems for Personal Healthcare by Smart Wearable Patch System. Biomolecules. 2023;13(6):929.

[78] Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018;16(1):71.